All The Most Important News and Updates form the Annual European Congress of Rheumatology – EULAR 2018
AbbVie Presented Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis
June 12, 2018
AbbVie, a research-based global biopharmaceutical company, has presented new patient-reported outcome data from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis. Improvements in pain, physical function and morning joint stiffness were reported after 12 weeks of treatment with upadacitinib (15 mg and 30 mg, once-daily) in SELECT-NEXT and SELECT-BEYOND and after 14 weeks of treatment in SELECT-MONOTHERAPY. Additionally, improvements were reported in fatigue and work instability in SELECT-NEXT and patients’ physical component of health-related quality of life in SELECT-NEXT and SELECT-BEYOND at 12 weeks. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
June 13, 2018
Novartis attended the Annual European Congress of Rheumatology (EULAR 2018) with 26 accepted abstracts reinforcing the roles of Cosentyx® (secukinumab) and IL-17A, cornerstone cytokine in the development of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Bristol-Myers Squibb Presented New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis
June 13, 2018
Bristol-Myers Squibb Company has confirmed that 31 abstracts demonstrating The Company’s immunoscience-research focus as well as how ORENCIA® (abatacept) therapy may impact diverse patient subgroups were presented aEULAR 2018 in Amsterdam.
Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
June 15, 2018
Horizon Pharma plc presents multiple analyses of KRYSTEXXA® (pegloticase injection) clinical trial data underscoring the complex nature of chronic gout refractory to conventional therapies, also known as uncontrolled gout. These data presented at EULAR demonstrate how elevated serum uric acid levels may have systemic effects across multiple organ systems and the need to manage uncontrolled gout aggressive.
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
June 15, 2018
Sandoz, a Novartis division, has announced the presentation of two long-term, Phase III studies: one each for biosimilar Zessly® (infliximab) and biosimilar Erelzi® (etanercept). Research from the 54-week REFLECTIONS B537-02 study of Zessly and the 48-week EQUIRA study of Erelzi showed that each biosimilar matched its reference biologic in terms of safety, efficacy and quality, reinforcing previously-presented findings.
A Product Manager with expertise in pharma marketing and sales operations